Mississippi's Board of Nursing, Board of Pharmacy, and State Board of Medical Licensure issued a joint statement on August 19, 2026 that leaves little room for interpretation: a healthcare provider may not compound, administer, dispense, recommend, supply, or prescribe non-FDA-approved "research-grade" peptides to patients. For Mississippi APRNs, that includes anyone running or working in a wellness, weight-loss, or aesthetics practice.

This is an NP-facing briefing, not legal advice. Everything below comes from the joint statement itself, which the Mississippi Board of Nursing posts on its homepage. If anything here differs from what the boards tell you, the boards win.

What the statement says

The three boards start from the product itself. Research-grade peptides are not FDA-approved and haven't been tested, reviewed, or found safe or effective for human use. The FDA doesn't oversee their safety, efficacy, manufacturing, or consistency, so neither the provider nor the patient can verify what's actually in a vial.

From there, the statement sets out several rules for licensees:

Where the line is

The statement draws one distinction worth knowing. If a patient gets these substances on their own and self-administers them, the risk rests with the patient. But once a medical professional is involved in recommending, supplying, prescribing, or administering them, the boards call that the practice of medicine and say it's prohibited.

The statement puts the risk on the patient only when the patient gets and uses the product on their own; any professional involvement in recommending, supplying, prescribing, or administering it is prohibited.

Who it affects

The statement is addressed to healthcare providers licensed by any of the three boards, so it reaches APRNs, physicians, and pharmacists alike. It was signed by the executive directors of all three boards, including Phyllis Polk Johnson, DNP, APRN, FNP-BC, FNAP, executive director of the Mississippi Board of Nursing.

It matters most for NPs who practice in medical spas, hormone and wellness clinics, weight-management programs, or any setting where peptide therapy is marketed.

What it is not

The statement is a joint position from the licensing boards, not a new administrative rule with its own section number, and it doesn't add CE hours or change renewal requirements. It also doesn't address FDA-approved peptide drugs prescribed and sourced through normal channels. Its target is non-FDA-approved peptides, including products sold as "research-grade."

What it does tell you is how all three boards expect licensees to behave, and that consent paperwork won't be treated as a defense.

What Mississippi NPs should do now

1. Read the statement. It's one page. Know what it covers before a patient or employer asks. 2. Review your practice's peptide offerings. If any product isn't FDA-approved, or is sold as research-grade, stop recommending, prescribing, or administering it. 3. Check your suppliers. Confirm each source is permitted by the Mississippi Board of Pharmacy, using its license verification search. 4. Don't rely on waivers. Retire any consent form that treats "research-grade" labeling as shifting the risk to the patient. 5. Ask the board if you're unsure. For questions about a specific product or arrangement, contact the Mississippi Board of Nursing. For supplier questions, the Board of Pharmacy lists 601-899-8880 in the statement.

Sources

This article is general information for nurse practitioners, not legal advice. Confirm your own obligations with the Mississippi Board of Nursing before you rely on it.

If you hold licenses in more than one state, CeMe Tracker keeps each state's CE hours, topics, and renewal deadlines in one place, and the free State Data Hub lets you look up any state's NP requirements.